查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964019

自体免疫肝炎诊断和治疗市场—全球产业规模、份额、趋势、机会和预测：按类型、诊断方法、治疗类型、地区和竞争对手划分，2021-2031年

Autoimmune Hepatitis Diagnosis And Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Diagnosis, By Treatment Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球自体免疫肝炎诊断和治疗市场预计将从 2025 年的 125.6 亿美元成长到 2031 年的 163.1 亿美元，复合年增长率为 4.45%。

自体免疫肝炎 (AIH) 是一种慢性发炎性疾病，患者的免疫系统会攻击肝细胞，因此需要进行准确的血清学鑑定和长期免疫抑制治疗。市场成长的主要驱动因素是全球自体免疫疾病盛行率的上升以及临床意识的增强，这有利于早期发现和介入。此外，可靠的诊断生物标记的出现有助于将 AIH 与其他肝臟疾病区分开来。英国肝臟信託基金会 (英国 Liver Trust) 2024 年的一项患者调查显示，16.7% 的肝病患者被确诊为自体免疫肝炎，凸显了该疾病带来的沉重负担。

市场概览
预测期 2027-2031
市场规模：2025年 125.6亿美元
市场规模：2031年 163.1亿美元
复合年增长率：2026-2031年 4.45%
成长最快的细分市场 1型
最大的市场 北美洲

然而，诊断的复杂性和疾病误诊率高阻碍了市场扩张。自体免疫肝炎的症状通常不明显，或与其他肝臟疾病的症状相似，导致诊断和治疗启动延迟。这种诊断上的不确定性，加上标准皮质类固醇疗法带来的严重副作用，常导致患者治疗顺从性低。这些因素使得制定维持市场成长所需的有效长期管理策略变得复杂。

市场驱动因素

新型生物製药和标靶免疫疗法的出现，为传统皮质类固醇疗法提供了替代方案，从根本上改变了市场格局。这项转变的驱动力在于产业结构大规模重组和旨在拓展自体免疫，旨在获得用于治疗系统性免疫疾病的先进小分子拮抗剂。这种强劲的投资环境正在加速推进针对肝臟自体免疫疾病的特定临床计画。尤其值得一提的是，2024年10月，Kether Life Sciences将研发重心转向针对自体免疫肝炎的PORTOLA IIa期临床试验，并利用约1.48亿美元的现金资金推动选择性免疫蛋白酶体抑制剂的开发。

同时，非侵入性诊断影像和生物标记技术的进步正在解决疾病误诊和检测延迟等长期存在的难题。识别准确的代谢特征对于在不依赖侵入性切片检查的情况下将自体免疫性肝炎与其他肝臟疾病区分开来至关重要。 2024年9月发表在《肝病学》（Hepatology）杂誌上的一项研究证实，一种由15种代谢物组成的新型代谢谱能够以95%的灵敏度区分自体免疫肝炎与其他肝臟疾病。这些诊断技术的飞跃对于促进早期疗育和确保患者获得适当的标靶治疗至关重要，并透过改善临床管理推动市场成长。

市场挑战

自体免疫肝炎 (AIH) 诊断的复杂性及其高误诊率是限制全球市场成长的重要阻碍因素。由于目前尚无针对该疾病的单一明确标记物，医疗服务提供者往往难以在不进行广泛检测的情况下将 AIH 与其他肝臟疾病（例如病毒性肝炎和代谢性肝病）区分开来。这种不确定性延长了诊断时间，延迟了必要的免疫抑制治疗的启动，并减少了疾病早期可治疗阶段的药物用量。因此，有效药物治疗的窗口期往往被缩短，从而限制了製药公司的商机。

这些诊断延迟的影响巨大，因为错失早期诊断机会可能导致疾病不可逆的进展，并降低标准药物治疗方案的疗效。根据美国肝病协会 (AASLD) 2024 年的数据，估计有 28% 至 33% 的自体免疫肝炎成年患者在首次临床评估时已发展为肝硬化。如此高的晚期诊断率表明，相当一部分患者错过了慢性病管理的早期阶段，阻碍了治疗市场的稳定成长。

市场趋势

将人工智慧 (AI) 整合到诊断演算法中，透过解决组织学变异性问题，正在革新肝臟自体免疫的评估。利用深度学习模型自动识别切片检查标本中的微观特征，我们实现了判读的标准化，并减少了使诊断复杂化的观察者间差异。此演算法的准确性在区分重迭的胆汁淤积性疾病方面尤其有效。例如，一项在 2024 年 6 月欧洲肝臟研究协会 (EASL) 年会上发表的研究表明，一种新型的基于 AI 的神经网路估计器能够区分自体免疫肝炎和原发性胆汁性肝炎，其受试者工作特征曲线下面积(AUROC) 达到了 0.81。这提高了诊断准确性并减少了误诊。

随着诊断技术的进步，B细胞清除剂的广泛应用正在重塑难治性疾病的治疗策略。抗CD20单株抗体可直接针对参与致病性自体抗体产生的免疫细胞，目前正迅速应用于临床实践，用于治疗对标准糖皮质激素无反应的患者。根据2024年5月发表于国际肝病研究学会官方期刊的一项註册研究分析，接受利Rituximab治疗的患者中有89%达到或维持了完全生化缓解。这种向标靶B细胞清除疗法的转变代表着治疗策略的重大革新，确保了对传统免疫抑制剂无反应的难治性患者群体的有效管理。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：自体免疫肝炎诊断与治疗的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（类型 1、类型 2）
    • 诊断方法（血液检查、切片检查、影像检查）
    • 治疗方法（药物治疗、手术、肝臟移植、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美自体免疫肝炎诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲自体免疫肝炎诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区自体免疫肝炎诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲自体免疫肝炎诊断和治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲自体免疫肝炎诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球自体免疫肝炎诊断与治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AbbVie, Inc.
  • ADC Therapeutics SA
  • AstraZeneca PLC
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hiedelberg Pharma A/G
  • Takeda Pharmaceutical Company Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27598

The Global Autoimmune Hepatitis Diagnosis And Treatment Market is projected to expand from USD 12.56 Billion in 2025 to USD 16.31 Billion by 2031, reflecting a compound annual growth rate of 4.45%. Autoimmune Hepatitis (AIH), a chronic inflammatory condition where the immune system targets liver cells, necessitates accurate serological identification and long-term immunosuppressive therapy. The market's growth is primarily driven by the increasing global prevalence of autoimmune disorders and heightened clinical awareness, which supports earlier detection and intervention. Furthermore, the availability of reliable diagnostic biomarkers helps differentiate AIH from other liver conditions. Underscoring the disease's burden, a 2024 patient survey by the British Liver Trust indicated that 16.7% of respondents with a liver condition were diagnosed specifically with autoimmune hepatitis.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.56 Billion
Market Size 2031USD 16.31 Billion
CAGR 2026-20314.45%
Fastest Growing SegmentType 1
Largest MarketNorth America

However, market expansion is hindered by the complexity of diagnosis and the frequent misclassification of the disease. AIH often manifests with vague symptoms or mimics other liver pathologies, resulting in delays in diagnosis and the start of treatment. This ambiguity, coupled with the significant side effects linked to standard corticosteroid therapies, often leads to poor patient compliance. These factors complicate the effective long-term management strategies required to sustain continuous market growth.

Market Driver

The emergence of novel biologics and targeted immunotherapies is fundamentally transforming the market by providing alternatives to traditional corticosteroid treatments. This transition is bolstered by substantial industry consolidation and financial investments aimed at broadening autoimmune product lines. For instance, in May 2024, Incyte completed its $750 million acquisition of Escient Pharmaceuticals to obtain advanced small molecule antagonists for systemic immune disorders. This strong investment environment is accelerating specific clinical programs for liver autoimmunity; notably, Kezar Life Sciences shifted its focus in October 2024 to the PORTOLA Phase 2a clinical trial for autoimmune hepatitis, utilizing a cash balance of approximately $148 million to advance its selective immunoproteasome inhibitor.

Simultaneously, advancements in non-invasive diagnostic imaging and biomarker technologies are addressing historical issues related to disease misclassification and delayed detection. Identifying precise metabolic signatures is becoming essential for distinguishing this pathology from other liver conditions without relying solely on invasive biopsies. A study published in the journal Hepatology in September 2024 validated a new metabolic profile comprising 15 metabolites capable of differentiating autoimmune hepatitis from other hepatic diseases with 95% sensitivity. These diagnostic breakthroughs are crucial for facilitating early intervention and ensuring patients receive appropriate, targeted therapies, thereby driving market growth through enhanced clinical management.

Market Challenge

The intricate nature of diagnosing Autoimmune Hepatitis (AIH) and the high rate of misclassification act as significant restraints on global market growth. Because the disease does not present a single definitive marker, healthcare providers frequently struggle to distinguish AIH from other hepatic disorders, such as viral hepatitis or metabolic liver conditions, without conducting extensive testing. This uncertainty results in prolonged diagnostic timelines, which delays the administration of essential immunosuppressive therapies and lowers prescription volumes during the early, treatable stages of the disease. Consequently, the window for effective pharmacological intervention often narrows, limiting the revenue potential for drug manufacturers.

The consequences of these diagnostic delays are substantial, as missed early diagnoses allow the pathology to progress to irreversible stages where standard drug regimens are less effective. Data from the American Association for the Study of Liver Diseases in 2024 estimates that 28% to 33% of adults with Autoimmune Hepatitis already present with cirrhosis at the time of their initial clinical assessment. This high incidence of late-stage diagnosis suggests that a significant portion of the patient population is missing the primary phase of chronic disease management, thereby impeding the consistent expansion of the therapeutic market.

Market Trends

The incorporation of Artificial Intelligence into diagnostic algorithms is revolutionizing the assessment of liver autoimmunity by addressing histological variability. Deep learning models are being utilized to automate the recognition of microscopic features on biopsy slides, thereby standardizing interpretation and reducing the inter-observer variability that complicates diagnosis. This algorithmic precision is especially valuable for distinguishing the disease from overlapping cholestatic conditions. For example, a study presented at the European Association for the Study of the Liver (EASL) annual congress in June 2024 demonstrated that a new AI-based neural estimator distinguished autoimmune hepatitis from primary biliary cholangitis with an area under the receiver operating characteristic curve (AUROC) of 0.81, enhancing diagnostic accuracy and reducing misclassification.

Concurrent with diagnostic advancements, the increasing utilization of B-cell depleting agents is reshaping the management of refractory disease. Clinicians are rapidly adopting anti-CD20 monoclonal antibodies for patients who do not respond to standard corticosteroids, directly targeting the immune cells responsible for producing pathogenic autoantibodies. A registry analysis published in the official journal of the International Association for the Study of the Liver in May 2024 indicated that 89% of patients treated with Rituximab achieved or maintained a complete biochemical response. This shift toward targeted B-cell depletion marks a critical evolution in therapeutic strategies, ensuring effective management for difficult-to-treat patient cohorts where conventional immunosuppressants fail.

Key Market Players

  • AbbVie, Inc.
  • ADC Therapeutics SA
  • AstraZeneca PLC
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Hiedelberg Pharma A/G
  • Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global Autoimmune Hepatitis Diagnosis And Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoimmune Hepatitis Diagnosis And Treatment Market, By Type

  • Type 1
  • Type 2

Autoimmune Hepatitis Diagnosis And Treatment Market, By Diagnosis

  • Blood Tests
  • Liver Biopsy
  • Imaging Tests

Autoimmune Hepatitis Diagnosis And Treatment Market, By Treatment Type

  • Medications
  • Surgery
  • Liver Transplant
  • Others

Autoimmune Hepatitis Diagnosis And Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoimmune Hepatitis Diagnosis And Treatment Market.

Available Customizations:

Global Autoimmune Hepatitis Diagnosis And Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Type 1, Type 2)
    • 5.2.2. By Diagnosis (Blood Tests, Liver Biopsy, Imaging Tests)
    • 5.2.3. By Treatment Type (Medications, Surgery, Liver Transplant, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnosis
    • 6.2.3. By Treatment Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnosis
        • 6.3.1.2.3. By Treatment Type
    • 6.3.2. Canada Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnosis
        • 6.3.2.2.3. By Treatment Type
    • 6.3.3. Mexico Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnosis
        • 6.3.3.2.3. By Treatment Type

7. Europe Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnosis
    • 7.2.3. By Treatment Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By Treatment Type
    • 7.3.2. France Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By Treatment Type
    • 7.3.3. United Kingdom Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By Treatment Type
    • 7.3.4. Italy Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnosis
        • 7.3.4.2.3. By Treatment Type
    • 7.3.5. Spain Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnosis
        • 7.3.5.2.3. By Treatment Type

8. Asia Pacific Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnosis
    • 8.2.3. By Treatment Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By Treatment Type
    • 8.3.2. India Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By Treatment Type
    • 8.3.3. Japan Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By Treatment Type
    • 8.3.4. South Korea Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By Treatment Type
    • 8.3.5. Australia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By Treatment Type

9. Middle East & Africa Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnosis
    • 9.2.3. By Treatment Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By Treatment Type
    • 9.3.2. UAE Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By Treatment Type
    • 9.3.3. South Africa Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By Treatment Type

10. South America Autoimmune Hepatitis Diagnosis And Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnosis
    • 10.2.3. By Treatment Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By Treatment Type
    • 10.3.2. Colombia Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By Treatment Type
    • 10.3.3. Argentina Autoimmune Hepatitis Diagnosis And Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By Treatment Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Autoimmune Hepatitis Diagnosis And Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ADC Therapeutics SA
  • 15.3. AstraZeneca PLC
  • 15.4. Genentech, Inc.
  • 15.5. Genmab A/S
  • 15.6. Gilead Sciences, Inc.
  • 15.7. GlaxoSmithKline PLC
  • 15.8. Pfizer, Inc.
  • 15.9. Hiedelberg Pharma A/G
  • 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer